M&G Investment Management Ltd. Acquires New Shares in Intuitive Surgical, Inc. (NASDAQ:ISRG)

M&G Investment Management Ltd. acquired a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 2,833 shares of the medical equipment provider's stock, valued at approximately $955,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. OFI Invest Asset Management purchased a new position in shares of Intuitive Surgical during the third quarter worth about $25,000. Baystate Wealth Management LLC increased its position in Intuitive Surgical by 150.0% during the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider's stock worth $25,000 after buying an additional 45 shares during the period. MCF Advisors LLC increased its holdings in shares of Intuitive Surgical by 108.1% in the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider's stock valued at $26,000 after acquiring an additional 40 shares during the period. Headinvest LLC purchased a new stake in Intuitive Surgical in the 3rd quarter valued at $28,000. Finally, Stone House Investment Management LLC grew its position in Intuitive Surgical by 100.0% during the 3rd quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider's stock worth $29,000 after purchasing an additional 50 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of the business's stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the transaction, the director now owns 25,319 shares of the company's stock, valued at $9,385,753.30. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the business's stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total value of $41,892,853.20. Following the transaction, the vice president now owns 26,877 shares of the company's stock, valued at $10,349,795.16. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Alan J. Levy sold 2,000 shares of the firm's stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the transaction, the director now owns 25,319 shares in the company, valued at approximately $9,385,753.30. The disclosure for this sale can be found here. Insiders have sold 148,259 shares of company stock worth $57,194,299 over the last three months. Company insiders own 0.90% of the company's stock.

Wall Street Analysts Forecast Growth

ISRG has been the subject of a number of recent analyst reports. Citigroup raised their price objective on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a "buy" rating in a research report on Wednesday, April 3rd. Royal Bank of Canada increased their target price on Intuitive Surgical from $400.00 to $432.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 24th. Wells Fargo & Company increased their target price on Intuitive Surgical from $363.00 to $416.00 and gave the stock an "overweight" rating in a research note on Friday, January 19th. Mizuho raised their price objective on Intuitive Surgical from $350.00 to $390.00 and gave the company a "neutral" rating in a research note on Thursday, January 25th. Finally, Raymond James raised their price objective on Intuitive Surgical from $372.00 to $435.00 and gave the company an "outperform" rating in a research note on Thursday, January 25th. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $396.17.

Intuitive Surgical Price Performance

NASDAQ:ISRG traded down $2.96 during trading hours on Thursday, reaching $396.43. The company's stock had a trading volume of 1,077,779 shares, compared to its average volume of 1,564,576. The company has a market cap of $140.61 billion, a price-to-earnings ratio of 71.89, a price-to-earnings-growth ratio of 4.92 and a beta of 1.39. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $403.76. The business's 50-day moving average is $384.75 and its 200-day moving average is $356.37.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping analysts' consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter in the previous year, the company earned $1.00 earnings per share. The business's revenue was up 11.5% compared to the same quarter last year. On average, sell-side analysts predict that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.